Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Heijman, J; Voigt, N; Dobrev, D.
New directions in antiarrhythmic drug therapy for atrial fibrillation.
Future Cardiol. 2013; 9(1): 71-88.
Doi: 10.2217/fca.12.78
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Heijman Jordi
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia and has a significant impact on morbidity and mortality. Current antiarrhythmic drugs for AF suffer from limited safety and efficacy, probably because they were not designed based on specific pathological mechanisms. Recent research has provided important insights into the mechanisms contributing to AF and highlighted several potential novel antiarrhythmic strategies. In this review, we highlight the main pathological mechanisms of AF, discuss traditional and novel aspects of atrial antiarrhythmic drugs in relation to these pathological mechanisms, and present potential novel therapeutic approaches including structure-based modulation of atrial-specific cardiac ion channels, restoring abnormal Ca(2+) handling in AF and targeting atrial remodeling.
- Find related publications in this database (using NLM MeSH Indexing)
- Anti-Arrhythmia Agents - chemistry, pharmacology, therapeutic use
- Atrial Fibrillation - drug therapy, etiology, pathology
- Heart Atria - drug effects, pathology, physiopathology
- Heart Conduction System - drug effects, pathology, physiopathology
- Humans - administration & dosage